Drug Profile
Research programme: c-Met kinase inhibitors - Merck
Latest Information Update: 26 Aug 2011
Price :
$50
*
At a glance
- Originator Merck & Co
- Class
- Mechanism of Action Proto-oncogene protein c-met inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 26 Aug 2011 No development reported - Preclinical for Cancer in USA (PO)
- 08 May 2007 Preclinical trials in Cancer in USA (unspecified route)